WGS
GeneDx Holdings Corp.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$69.52
+1.27%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$70.10
From 52W high−58.50%
Volume227908.00
Market cap$2.07B
P/E (TTM)—
P/S (TTM)4.6x
Div yield—
Key dataNov 4, 2026
Open
$70.10
From 52W high
−58.50%
Volume
227908.00
Market cap
$2.07B
ValuationView details →
P/E (Fwd)
80.5x
EV/EBITDA
−27.6x
P/E (TTM)
—
RSI (14)
48.4
MomentumView details →
1D Return
+1.27%
YTD Return
−47.48%
SummaryUpdated Jun 1, 2026
GeneDx Holdings Corp. (NASDAQ:WGS) is a patient-centered health intelligence company founded by Eric Schadt in October 2015 and headquartered in Stamford, Connecticut. The company went public in November 2020 and has established itself as a leader in genetic testing, particularly in pediatric and rare disease genomics. GeneDx operates the Centrellis health intelligence platform, which applies artificial intelligence and machine learning to clinical and genomic data to build comprehensive models of human health and provide personalized medical insights.
Similar companies
Latest newsMore news →
GeneDx Holdings Corp. announced that it will release its third-quarter 2026 financial results after the market closes on November 9, 2026, and hold a conference call at 4:30 p.m. Eastern Time that day.12d agoGeneDx Holdings Corp. announced that 27 scientific abstracts had been accepted for the American Society of Human Genetics 2026 Annual Meeting.16d ago